Study Design and Participants
toxicity
ONCOLOGY, LYMPHOMA, SECONDARY, SOLID TUMORS
This secondary analysis uses data from the GAP70+ trial, a nationwide study conducted in the University of Rochester NCI Community Oncology Research Program (UR NCORP). Community oncology practices were randomized to GA intervention or usual care. Eligible patients were age ≥ 70 years, had incurable solid tumors or lymphoma, at least one GA domain impairment other than polypharmacy, and were initiating a new systemic treatment regimen with a > 50% prevalence of grade 3-5 toxicity. Because of the high prevalence of polypharmacy in older adults